VK2735, developed by Viking Therapeutics, is positioned to address the significant market for weight management in patients with Type 2 Diabetes Mellitus (T2DM), particularly among those who are obese or overweight. The obesity treatment market is expanding rapidly, driven by increasing prevalence rates and a growing focus on metabolic health. VK2735's dual mechanism of action may provide a competitive edge over existing therapies, particularly GLP-1 receptor agonists, by potentially enhancing weight loss efficacy and improving glycemic control. The trial's design, being a multicenter, randomized, double-blind, placebo-controlled study, aligns with regulatory expectations and may facilitate a smoother path to market approval. However, the exclusion of certain diabetes treatments may limit the patient population and affect recruitment timelines. The anticipated primary completion date in July 2027 suggests a potential market entry in late 2028 or early 2029, contingent upon successful trial outcomes.